MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Pancreas, Pancreatic
Halozyme Therapeutics, Inc. (NASDAQ: HALO)*
Organization & Developments: Halozyme
Parents
Halozyme Therapeutics, Inc. (NASDAQ: HALO)*
Children
*Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics.
*Halozyme's other products include Hylenex (infusion agent), Enhanze SC (ophthalmic surgery anesthesia) and Chemophase (solid tum
*Intellectual Property Covering the Family of Human Enzymes Known as Hyaluronidases.
*Its first partnership is with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets
*Its manufacturing and distribution partners include Avid Bioservices (a subsidiary of Peregrine Pharmaceuticals), Baxter Interna
*Makes enzymes for infertility, cancer, and eye surgery applications.
*The company's products are based on recombinant human PH20, a human synthetic enzyme it hopes will offer safety benefits over an
2005: The development-stage firm launched its first commercial product, Cumulase (in-vitro fertilization), in 2005.
2017: Halozyme dips after pancreatic cancer trial halted for futility
2018: Halozyme: Explaining The Change In Trial Design_seekingalpha.com
2018: Why Halozyme Went Down Yesterday? - Halozyme Therapeutics, Inc. (NASDAQ:HALO)
2021: Halozyme: Nice Pivot To A Royalty Business
2022: Halozyme Looks Good For Their Excellent Royalty Revenue Stream_ seekingalpha.com
2022: Halozyme Therapeutics, Inc. 2022 Q3 - Results - Earnings Call Presentation_seekingalpha.com
2022: Halozyme Therapeutics: A Pharma Mutual Fund In A Single Company_ seekingalpha.com
2023: Halozyme Therapeutics: Chugging Along_seekingalpha.com
2024: Halozyme Therapeutics, Argenx Expand Global Collaboration & License Agreement
2024: Halozyme Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
2024: Halozyme Therapeutics: Behind The Pullback
2024: Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal
2024: Halozyme: Recent Approvals Alter My Appetite
2024: Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
2024: How Small Biotech Halozyme, With A 41% Run, Is Getting Under Your Skin
2024: Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
2024: Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
2024:Halozyme offers $2B for Evotec to expand beyond delivery tech used by J&J and Roche
2025: Halozyme Therapeutics: Steady Growth In A Challenged Marketseekingalpha.com
2025: Halozyme Therapeutics: The Waters Become Muddled
2025: Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025_seekingalpha.com
2026: AI Exhaustion? 3 Healthcare Stocks With 38% EPS Growth That Could Be the Cure
2026: Halozyme: The Market May Be Underpricing The Second Growth Wave (NASDAQ:HALO) | Seeking Alpha
Jumps
*Key People: Halozyme
Finance & Acquisitions: Halozyme